A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents
JACC: Cardiovascular Interventions · 2025-01 · 18 (1) · 15-27
DOI: 10.1016/j.jcin.2024.09.043 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-01. Verfasst von Shengwen Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. Hauptthemen laut MEDLINE: Absorbable Implants, Everolimus, Drug-Eluting Stents, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: First-generation bioresorbable scaffolds (BRS) increased risks of stent thrombosis and adverse events. The Bioheart scaffold is a new poly-L-lactic acid-based BRS. OBJECTIVES: This study sought to evaluate the efficacy and safety of the BRS in patients with coronary artery disease. METHODS: This was a prospective, multicenter, randomized, noninferiority trial comparing the Bioheart BRS with a cobalt-chromium everolimus-eluting stent (CoCr-EES) in patients with coronary artery disease. Angiography was planned at 12 months in all patients. The primary endpoint was 12-month in-segment late loss. The key secondary endpoint was the 12-month proportion of covered struts assessed on optical coherence tomography. Three-year clinical follow-up was completed. RESULTS: A total of 434 patients from 22 Chinese sites were included (Bioheart BRS, n =218; CoCr-EES, n = 216). One-year in-segment late loss was 0.17 ± 0.38 mm with the Bioheart BRS vs 0.14 ± 0.24 mm with CoCr-EES; the 1-sided 97.5% upper confidence limit of the difference was 0.10 mm (P for noninferiority < 0.0001). The proportion of covered struts was 97.9% in the Bioheart BRS and 98.5% in the CoCr-EES (difference 0.02%; 95% CI: -0.3% to 0.26%; P for noninferiority < 0.0001; P for superiority = 0.91). Clinical outcomes at 3 years were similar in the 2 groups, as were the rates of target lesion failure (5.6% vs 5.2%; P = 0.84). CONCLUSIONS: In this multicenter randomized trial, the Bioheart BRS was noninferior to the CoCr-EES for 1-year in-segment late loss, and resulted in a comparable 3-year clinical outcome. (Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study; NCT03284255).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Cardiology, Liaocheng People's Hospital, Liaocheng, China.
- Department of Cardiology, Sir Run Run Shaw hospital, Zhejiang University School of Medicine, Zhejiang, China.
- Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Zitieren
APA
Liu, S., Nie, S., Hou, Y., Huang, G., Fu, G., Zhou, H., Wei, M., Lu, F., Zhang, F., Wang, L., Wang, Y., Wu, Y., Qiao, S., & BIOHEART-II Investigators (2025). A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 18(1), 15-27. https://doi.org/10.1016/j.jcin.2024.09.043
Vancouver
Liu S, Nie S, Hou Y, Huang G, Fu G, Zhou H, et al. A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents. JACC: Cardiovascular Interventions. 2025;18(1):15-27. doi:10.1016/j.jcin.2024.09.043
BibTeX
@article{Liu2025,
author = {Liu, Shengwen and Nie, Shaoping and Hou, Yuqing and Huang, Guangyong and Fu, Guosheng and Zhou, Hua and Wei, Meng and Lu, Feng and Zhang, Feng and Wang, Lefeng and Wang, Yang and Wu, Yongjian and Qiao, Shubin and BIOHEART-II Investigators, BIOHEART-II Investigators},
title = {A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {1},
pages = {15--27},
doi = {10.1016/j.jcin.2024.09.043}
}
EUVIMED